http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2020171113-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2020-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2020171113-A1 |
| titleOfInvention | Pharmaceutical Compositions and Therapeutic Methods for Treating FGFR1 Mutation-Positive Brain Tumors |
| abstract | (S) -1- (3- (4-Amino-3-((3,5-dimethoxyphenyl) ethynyl) -1H-pyrazolo [3,4-d] pyrimidin-1-yl) pyrrolidine-1-yl) Provided are a pharmaceutical composition for treating a patient with FGFR1 mutation-positive brain tumor containing propa-2-ene-1-one or a pharmaceutically acceptable salt thereof as an active ingredient, and a therapeutic method using the pharmaceutical composition. do. |
| priorityDate | 2019-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.